Table 3.
Comparison: mITT SVR12 in treatment‐naïve patients without cirrhosis
| Subgroup | 8 weeks | 12 weeks | P value* |
|---|---|---|---|
| SVR12, n/N (%) | |||
| Race | |||
| Black | 5/5 (100) | 5/5 (100) | N/A |
| Non‐black | 193/198 (98) | 275/279 (99) | 0.5 |
| HCV RNA | |||
| <800 000 IU/mL | 85/86 (99) | 108/108 (100) | 0.4 |
| ≥800 000 IU/mL | 113/117 (97) | 172/176 (98) | 0.7 |
| Fibrosis stage | |||
| F0‐F2 | 165/168 (98) | 250/254 (98) | 1 |
| F3 | 33/35 (94) | 30/30 (100) | 0.5 |
| History of injection drug use | |||
| Yes | 133/136 (98) | 174/178 (98) | 1 |
| No | 65/67 (97) | 106/106 (100) | 0.1 |
| Recenta injection drug use | |||
| Yes | 18/18 (100) | 16/17 (94) | 0.5 |
| No | 98/101 (97) | 140/143 (98) | 0.7 |
| Opioid substitution therapy | |||
| Yes | 37/37 (100) | 41/42 (98) | 1 |
| No | 161/166 (97) | 239/242 (99) | 0.3 |
| Baseline NS5A polymorphism(s)b | |||
| Yes | 56/59 (95) | 49/52 (94) | 1 |
| No | 140/142 (99) | 226/227 (99) | 0.6 |
| Baseline A30K | |||
| Yes | 15/18 (83) | 13/14 (93) | 0.6 |
| No | 181/183 (99) | 263/266 (99) | 1 |
| Baseline Y93H | |||
| Yes | 10/10 (100) | 12/14 (86) | 0.5 |
| No | 186/191 (97) | 264/266 (99) | 0.1 |
mITT, modified intention‐to‐treat; SVR12, sustained virologic response at posttreatment week 12.
a
<12 months prior to screening; recent drug use data were not captured for patients enrolled in SURVEYOR‐2.
b
Includes patients with available baseline NS5A sequence data; amino acid positions included in the analysis: 24, 28, 30, 31, 58, 92, 93 in NS5A.
*
P value was calculated by Fisher's exact test.